KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Taxes (2017 - 2020)

Historic Current Taxes for Aquestive Therapeutics (AQST) over the last 4 years, with Q4 2020 value amounting to $316000.0.

  • Aquestive Therapeutics' Current Taxes rose 533.33% to $316000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $316000.0, marking a year-over-year increase of 533.33%. This contributed to the annual value of $316000.0 for FY2020, which is 533.33% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Current Taxes of $316000.0 as of Q4 2020, which was up 533.33% from $370000.0 recorded in Q1 2020.
  • In the past 5 years, Aquestive Therapeutics' Current Taxes ranged from a high of $388000.0 in Q4 2018 and a low of $176000.0 during Q2 2019
  • Moreover, its 4-year median value for Current Taxes was $327000.0 (2018), whereas its average is $312500.0.
  • In the last 5 years, Aquestive Therapeutics' Current Taxes crashed by 3307.98% in 2019 and then skyrocketed by 533.33% in 2020.
  • Quarter analysis of 4 years shows Aquestive Therapeutics' Current Taxes stood at $372000.0 in 2017, then increased by 4.3% to $388000.0 in 2018, then dropped by 22.68% to $300000.0 in 2019, then grew by 5.33% to $316000.0 in 2020.
  • Its last three reported values are $316000.0 in Q4 2020, $370000.0 for Q1 2020, and $300000.0 during Q4 2019.